Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.
Synthekine has raised $100.0M in total funding. The most recent round was Series C. The last funding was announced in January 2023.
Synthekine's investors include RA Capital Management, Lilly Asia Ventures, Janus Henderson Investors, TCG Crossover, Canaan Partners.
Synthekine is headquartered in Menlo Park, United States.
Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.
Synthekine is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Synthekine — Funding & Investors." VCBacked, January 6, 2023, https://www.vcbacked.co/company/synthekine. Accessed August 14, 2026.
VCBacked. (2023). Synthekine — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/synthekine
{{cite web |title=Synthekine — Funding & Investors |url=https://www.vcbacked.co/company/synthekine |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated